Form 4: ALX Oncology President & CSO Jaume Pons Executes Option and Sells Shares Under 10b5-1 Plan

Jaume Pons, President & CSO of ALX Oncology Holdings Inc, exercised stock options and sold 20,000 shares of common stock at a weighted average price of $15.9167 on May 6, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 6, 2024, Jaume Pons, the President & CSO of ALX Oncology Holdings Inc., executed an employee stock option to acquire 20,000 shares of common stock at a price of $0.99 per share.
• Simultaneously, Pons sold 20,000 shares of common stock at a weighted average price of $15.9167, with prices ranging from $15.55 to $16.3942.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 6, 2023.
• Following these transactions, Pons directly owns 604,205 shares of ALX Oncology common stock and holds options for 184,433 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment. The filing reflects routine insider trading activity under a pre-arranged plan. While the sale of shares could be perceived negatively, the existence of the 10b5-1 plan mitigates concerns about opportunistic selling.

Positives

• The exercise of stock options demonstrates the executive's belief in the company's long-term potential, as they are willing to invest in the company's stock.
• The use of a 10b5-1 trading plan suggests a structured and transparent approach to selling shares, mitigating concerns about insider trading.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by investors, potentially signaling a lack of confidence in the company's short-term prospects.

Risks

• Continued sales by insiders, even under 10b5-1 plans, could exert downward pressure on the stock price.
• Investor sentiment could be negatively impacted if there is a perception that executives are cashing out their holdings.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when company insiders engage in transactions involving the company's securities. It provides transparency to investors regarding the trading activities of key personnel.

Comparison to Industry Standards

• Insider trading activity is common in publicly traded companies, particularly in the biotechnology sector where stock options are a significant part of executive compensation.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading, similar to practices at companies like Amgen or Gilead Sciences.
• The reported weighted average sale price of $15.9167 is within the typical range observed for similar transactions in comparable biotech firms.

Stakeholder Impact

• Shareholders may react to the news of insider selling, potentially impacting the stock price.
• Employees may be concerned about the executive's confidence in the company, although the 10b5-1 plan provides context.

Key Dates